NCT07899307|Not Yet RecruitingPhase 3DMC
Metformin in Acute Ischemic Stroke
Efficacy of Oral Metformin in Acute Ischemic Stroke (AIS): a Multicentric Randomized Controlled Trial
Loading search results
Sponsor study identifier
interventional
440
1 country
4
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 28, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this clinical trial is to study the efficacy of oral Metformin in Acute Ischemic Stroke (AIS). The main hypothesis is to study the efficacy of oral Metformin in patients with acute ischemic stroke presenting within 72 hours of onset in terms of goof modified Rankin scale (mRS) at 90 days. Researchers will compare placebo tablets. Participants will randomised to Metformin or placebo in 1:1 ratio. Additionally, the blood sample will be collected to look for biomarkers hsCRP, Vitamin B12, and Holotranscobalamin at baseline and follow-up.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 7, 2026
Actual (reported)October 27, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 28, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
modified Rankin Scale (0 to 6, with 0 being no disability and 6 being death)
Good outcome (defined as modified Rankin Scale of 0-1) at 90 days
90 days
modified Rankin Scale (0 to 6, with 0 being no disability and 6 being death)
30 days
Mortality
30 days
Mortality
90 days
Barthel Index (0 to 100 with 0 being completely dependent to 100 being completely independent)
30 days
Barthel Index (0 to 100 with 0 being completely dependent to 100 being completely independent)
90 days
Identical placebo tablets will be provided
Metformin
Postgraduate Institute of Medical Education and Research
Chandigarh, Chandigarh, India
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, 110023, India
Jawaharlal Institute of Postgraduate Medical Education and Research
Puducherry, Puducherry, India
First Submitted
October 7, 2026
First Posted
October 27, 2026
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Institute of Medical Sciences, Banaras Hindu University
Varanasi, India
Primary Completion
October 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 28, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 29, 2026
Record last verified: 2026-09
Will be shared on request to the PI
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: